產(chǎn)品搜索
相關(guān)文章
- 羅氏免疫療法獲FDA批準(zhǔn)治療晚期非小細(xì)胞肺癌(NSCLC)
- 從諾輝財(cái)報(bào)看甲基化市場(chǎng),科佰生物助力甲基化標(biāo)準(zhǔn)品的開(kāi)發(fā)
- GLP1R藥靶篩選模型應(yīng)用展示
- 拯救偏頭痛!CGRP及其受體拮抗劑研究進(jìn)展
- 【產(chǎn)品推介】RANKL抗體篩選模型
- ATCC細(xì)胞的實(shí)驗(yàn)要點(diǎn)及說(shuō)明
- CD27細(xì)胞篩選模型
- 黑色素瘤研究進(jìn)展一覽
- CD200/CD200R篩選模型
- 認(rèn)識(shí)下北京細(xì)胞庫(kù)的質(zhì)量管理要求
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73255CSF3R S783fs/BaF3

- 詳細(xì)內(nèi)容
CBP73255 | |
I. Introduction | |
Cell Line Name: | CSF3R S783fs/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
CSF3R S783fs results in a change in the amino acid sequence of the Csf3r protein beginning at aa 783 of 836, likely resulting in premature truncation of the functional protein (UniProt.org). S783fs does not result in increased Stat3 activation (PMID: 23656643, PMID: 24403076), however, results in increased Src activation and transformation in cell culture (PMID: 23656643), and therefore, is predicted to result in a gain of Csf3r protein function. | |
III. Representative Data | |
1.WB of CSF3R S783fs/BaF3 | |
2. Anti-proliferation assay | |
Figure 2. Anti-proliferation assay of three reference compounds on the CSF3R S783fs/BaF3. |